The impact of peroxisome proliferator‐activated receptor‐γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy

The impact of peroxisome proliferator‐activated receptor‐γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy

Abstract Background Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte‐mediated antitumor activity. Methods We conducte...

Full description

Bibliographic Details
Main Authors:	Cho‐Han Chiang, Yu‐Cheng Chang, Shih‐Syuan Wang, Yuan‐Jen Chen, Xin Ya See, Chun‐Yu Peng, Yuan Ping Hsia, Cho‐Hsien Chiang, Cho‐Hung Chiang, Cheng‐Ming Peng
Format:	Article
Language:	English
Published:	Wiley 2023-04-01
Series:	Cancer Medicine
Subjects:	angiotensin receptor blockers immune checkpoint inhibitors peroxisome proliferator‐activated receptor‐γ renin‐angiotensin‐aldosterone system inhibitors
Online Access:	https://doi.org/10.1002/cam4.5734

Similar Items

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2022-12-01)

Survival Benefit of Renin-Angiotensin System Blockers in Critically Ill Cancer Patients: A Retrospective Study
by: Driss Laghlam, et al.
Published: (2023-06-01)

Renin-angiotensin system blockers and COVID-19
by: Emmanuelle Vidal-Petiot, et al.
Published: (2021-06-01)

Clinical pharmacogenetics of angiotensin II receptor blockers in Iraq
by: Hany A Al-Hussaniy, et al.
Published: (2023-01-01)

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study
by: Francisco J. de Abajo, et al.
Published: (2021-05-01)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
by: Seok Hui Kang, et al.
Published: (2023-05-01)

Angiotensin receptor blocker-induced bilateral ciliochoroidal effusion
by: Kanika Aggarwal, et al.
Published: (2020-01-01)

Assessment of optimal renin-angiotensin-system inhibition strategy in Asian patients with STEMI after primary myocardial revascularization
by: Hye-Jin Park, et al.
Published: (2022-01-01)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
by: Tao Liu, et al.
Published: (2023-01-01)

A Study of Morphological Changes in Renal Afferent Arterioles Induced by Angiotensin II Type 1 Receptor Blockers in Hypertensive Patients
by: Yohko Nagai, et al.
Published: (2020-01-01)

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
by: Jordan Loader, et al.
Published: (2022-06-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

Effect of angiotensin II type 1 receptor blocker and angiotensin converting enzyme inhibitor on the intraocular growth factors and their receptors in streptozotocin-induced diabetic rats
by: Ik Soo Byon, et al.
Published: (2017-06-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: Maksimov M.L., et al.
Published: (2017-02-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: M L Maksimov, et al.
Published: (2017-03-01)

Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
by: Jenny I. Shen, et al.
Published: (2017-06-01)

Effect of ACEi and ARBs vs Non ACEi/ARBs in Hypertension with Respect to Renal Outcomes in COVID-19 Infection: A Retrospective Cohort Study
by: S Ravitej, et al.
Published: (2022-11-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Angiotensin receptor blockers in heart failure after the ELITE II trial
by: Willenheimer Ronnie
Published: (2000-09-01)

Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
by: Simon B. Gressens, et al.
Published: (2021-02-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
by: Selçuk Şen, et al.
Published: (2020-10-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement
by: Fabrizio Buffolo, et al.
Published: (2021-05-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Comparison of Angiotensin‐Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial
by: Sean van Diepen, et al.
Published: (2018-10-01)

Place of angiotensin receptor blockers in antihypertensive therapy
by: A I Martynov, et al.
Published: (2014-03-01)

Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease
by: Terry Huh, et al.
Published: (2021-01-01)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
by: Ju Hwan Kim, et al.
Published: (2020-12-01)

The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease
by: Stine Andersen, et al.
Published: (2016-06-01)

Angiotensin‐Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID‐19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System
by: Jaejin An, et al.
Published: (2021-02-01)

Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer
by: Marcin Zeman, et al.
Published: (2022-07-01)